Articles From: CWB announces normal course issuer bid for preferred shares to Cyclacel Pharmaceuticals Announces $20 Million Underwritten Offering


2013/3/6
Sign-up for CWB announces update on shareholder meetings investment picks
2013/3/7
CWB appoints Chris Fowler as President and Chief Executive Officer Canada NewsWire EDMONTON , March 7, 2013 /CNW/ - Canadian Western Bank (TSX: CWB) (CWB or the Bank) today announced the official appointment of Chris Fowler as President and Chief Executive Officer (CEO). While the expectation of this leadership transition has already been widely communicated, it was officially confirmed today by a positive vote of shareholders at the Bank's 2013 Annual and Special Meeting.
Sign-up for CWB appoints Chris Fowler as President and Chief Executive Officer investment picks
2013/3/7
CWB reports strong financial performance as total assets surpass $17 billion Canada NewsWire Solid loan growth of 2% in the quarter and 12% over the past year Quarterly dividend declared of $0.17 per CWB common share Quarterly dividend declared on CWB preferred shares First Quarter 2013 Highlights 1 (compared to the same period in the prior year) Net income available to common shareholders of $45.5 million, up 10%. Diluted earnings per common share of $0.57, up 6%; adjusted cash earnings per common share of $0.58, up 2%. Total revenues, on a taxable equivalent basis (teb), of $137.1 million, up 9%. Total assets surpassed $17 billion based on strong loan growth of 12% over the past twelve months.
Sign-up for CWB reports strong financial performance as total assets surpass $17 billion investment picks
2013/4/23
CWB to invest in wealth management firm, McLean & Partners Canada NewsWire About Canadian Western Bank  Canadian Western Bank offers a full range of business and personal banking services across the four western provinces and is the largest publicly traded Canadian bank headquartered in Western Canada .
Sign-up for CWB to invest in wealth management firm, McLean & Partners investment picks
2013/4/30
Cyalume Technologies Holdings, Inc. (OTCBB: CYLU) (“the Company” or “Cyalume”) today announced that it has appointed Michael J.
Sign-up for Cyalume Technologies Holdings, Inc. Appoints Michael J. Pellicci as Chief Financial Officer investment picks
2013/5/6
Cyalume Technologies Holdings, Inc. (OTCBB: CYLU) (“the Company” or “Cyalume”) today reported its financial results for the first quarter ended March 31, 2013.
Sign-up for Cyalume Technologies Holdings, Inc. Reports First Quarter 2013 Financial Results investment picks
2013/3/26
Cyalume Technologies Holdings, Inc. (OTCBB: CYLU) (“the Company” or “Cyalume”) today reported its financial results for the fourth quarter and year ended December 31, 2012.
Sign-up for Cyalume Technologies Holdings, Inc. Reports Fourth Quarter and Fiscal Year 2012 Financial Results investment picks
2013/3/18
Cyan and Nistica today announced a joint development agreement to build high-capacity linecards that provide multi-degree reconfigurable optical add-drop multiplexing (ROADM) capabilities.
Sign-up for Cyan and Nistica Announce Next-Generation Linecard Development Agreement investment picks
2013/5/8
http://media.marketwire.com/attachments/201305/60926_cyanlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1015286&ProfileId=051205&sourceType=1 PETALUMA, CA --
Sign-up for Cyan Announces Pricing of Initial Public Offering investment picks
2013/5/9
Petaluma, Cailf.-based Cyan, a global supplier of software defined networking (SDN) solutions, opened for trading today on the New York Stock Exchange (NYSE) under the ticker symbol “CYNI” after its initial public offering.
Sign-up for Cyan Celebrates Initial Public Offering and First Day of Trading on the New York Stock Exchange investment picks
2013/2/7
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the third quarter and first nine months of fiscal year 2013, ended December 31, 2012.
Sign-up for Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013 investment picks
2013/5/16
South Carolina students will now have access to another industry-leading virtual learning option for the 2013-2014 school year GREENVILLE, S.C. , May 16, 2013 /PRNewswire/ --  Cyber Academy of South Carolina (CASC), a new full-time, tuition-free online public school option, announced that they are now enrolling students entering grades K through 9 for the 2013-2014 school year, with plans to add an additional three grade levels over the next three years.
Sign-up for Cyber Academy of South Carolina (CASC) Opens Statewide Enrollment for Students Entering Grades K Through 9 investment picks
2013/5/8
Keynote ® (NASDAQ: KEYN) , the global leader in Internet and mobile cloud testing and monitoring , today announced that Shawn White, vice president of operations, will be speaking at the Security 500 Conference on a panel entitled, “Cyber Warfare on Your Enterprise: Is that Real or Hype?” Shawn will share the latest data Keynote has uncovered regarding ongoing aggressive attacks on the websites of leading U.S. banks, as well as Keynote’s experience in identifying DDoS (distributed denial of service) attacks and how companies are learning to better protect themselves.
Sign-up for Cyber Warfare is Main Topic of Discussion at Security 500 Event – Keynote’s VP of Operations Shawn White to Present Latest Data on Bank Site Attacks investment picks
2013/4/18
Users should be cautious when receiving emails about "breaking news" or "exclusive videos" as additional email attacks are likely MCLEAN, Virginia , April 18, 2013 /PRNewswire/ -- Commtouch ® (NASDAQ: CTCH) , a leading provider of Internet security technology and cloud-based services, warns that cybercriminals have begun exploiting Monday's terrorist attacks on the 2013 Boston Marathon in malware email campaigns discovered by Commtouch's research labs.
Sign-up for Cybercriminals Exploit Boston Bombings in Malware Email Campaign investment picks
2013/2/4
HOUSTON , Feb.
Sign-up for Cyberonics Announces Update On Hagerty Lawsuit investment picks
2013/4/4
HOUSTON , April 4, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today provided an update on its recent submission to the Centers for Medicare & Medicaid Services ("CMS") seeking reimbursement coverage for the treatment-resistant depression ("TRD") indication for the VNS Therapy ® System.
Sign-up for Cyberonics Provides Update On Submission To CMS investment picks
2013/2/22
Sales of $63 million - 15% Growth Income from Operations increases by 25% Provides Depression Update HOUSTON , Feb.
Sign-up for Cyberonics Reports Fiscal 2013 Third Quarter Results investment picks
2013/2/13
HOUSTON , Feb.
Sign-up for Cyberonics to Participate in Upcoming Investor Conferences investment picks
2013/5/7
HOUSTON , May 7, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today announced that the company will report financial results for the fourth quarter and fiscal year ended April 26, 2013 , on Wednesday, June 5, 2013 , before regular market trading hours.
Sign-up for Cyberonics To Report Fourth Quarter And Fiscal Year 2013 Results And Host Webcast And Conference Call On June 5, 2013 investment picks
2013/4/10
CyberOptics Corporation (Nasdaq: CYBE) today announced that it will hold its conference call to review operating results for the first quarter of 2013 on Wednesday, April 24 at 4:30 pm Eastern.
Sign-up for CyberOptics First Quarter 2013 Conference Call Scheduled for April 24 investment picks
2013/2/11
CyberOptics Corporation (Nasdaq: CYBE) today announced that it will hold its conference call to review operating results for the fourth quarter of 2012 on Monday, February 25 at 4:30 pm Eastern.
Sign-up for CyberOptics Fourth Quarter 2012 Conference Call Scheduled for February 25, 2013 investment picks
2013/4/24
CyberOptics Corporation (Nasdaq: CYBE) today reported consolidated sales of $6.7 million for the first quarter of 2013 ended March 31, down from $11.3 million in the year-earlier period, reflecting our previously forecasted impact of weak conditions in the SMT capital equipment market.
Sign-up for CyberOptics Reports First Quarter Operating Results investment picks
2013/2/25
CyberOptics Corporation (Nasdaq: CYBE) today reported consolidated sales of $5.8 million for the fourth quarter of 2012 ended December 31, down from $13.8 million in the year-earlier period as the downturn in the global electronics market deepened considerably during the quarter.
Sign-up for CyberOptics Reports Fourth Quarter Operating Results investment picks
2013/5/3
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0871294001&sourceType=1 http://media3.marketwire.com/docs/cx514logo.jpg TORONTO, ONTARIO --
Sign-up for Cyberplex Rebrands, Changes Name to EQads investment picks
2013/3/5
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0857742001&sourceType=1 http://media3.marketwire.com/docs/cx514logo.jpg TORONTO, ONTARIO --
Sign-up for Cyberplex's EQ Ads Goes Mobile investment picks
2013/2/6
Cybex International, Inc. (NASDAQ: CYBI) , a leading U.S. manufacturer of premium exercise equipment (“Cybex” or the “Company”), announced today that the proposed “going private” merger pursuant to which each of its outstanding shares of common stock - other than shares owned by its largest shareholder, UM Holdings, Ltd.
Sign-up for Cybex Announces Shareholder Approval of “Going Private” Merger investment picks
2013/4/3
BERKELEY HEIGHTS, N.J., April 3, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that two abstracts highlighting clinical and preclinical data for Cyclacel's cell cycle inhibitor drugs have been selected for an oral presentation during a Clinical Trials symposium and a poster presentation at the American Association for Cancer Research (AACR) annual meeting, being held April 6-10, 2013, at the Walter E.
Sign-up for Cyclacel Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting investment picks
2013/4/4
BERKELEY HEIGHTS, N.J., April 4, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced that it has entered into a definitive agreement with Celgene Corporation ("Celgene") to sell to Celgene four Cyclacel‐owned patents related to the use of romidepsin injection.
Sign-up for Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene and Dismissal of All Claims in Their Patent Litigation investment picks
2013/5/16
BERKELEY HEIGHTS, N.J., May 16, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced the pricing of the underwritten offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share.
Sign-up for Cyclacel Pharmaceuticals Announces $20 Million Underwritten Offering investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: CWB announces normal course issuer bid for preferred shares to Cyclacel Pharmaceuticals Announces $20 Million Underwritten Offering
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity